Bardoxolone methyl (Bard)-mediated strong suppression of calcium oxalate crystal formation in renal crystal recurrence model Authors: Chiharuko Ushimoto, Ryoko Akai, Shigeru Sugiki, Kenshiro Kunii, Shinya Inoue, Takao Iwawaki, Katsuhito Miyazawa Published: 2025 ABSTRACT The oxidative stress response during renal crystal recurrence and the dynamics of calcium oxalate (CaOx) crystal formation and clearance in a glyoxylate (GOX)-induced mouse model were examined. CaOx crystals gradually accumulated during five consecutive days of GOX administration, decreased by half in the ten days after administration, and required five weeks for near-complete clearance. HO-1 expression was strongly induced by the initial GOX administration through Nrf2 activation but diminished on continuing the administration. When GOX was readministered after a 10-day interval, HO-1 induction was minimal; however, after a 5-week interval, HO-1 expression returned to its initial levels. Readministration of GOX after crystal clearance resulted in reduced crystal formation and individual differences in crystal volume compared with the initial episode. Preadministration of bardoxolone methyl (Bard), a potent Nrf2 activator, significantly suppressed recurrent CaOx crystal formation. These findings strongly suggest the existence of an interaction between oxidative stress responses and renal crystal recurrence, highlighting the potential of Nrf2 activation as a preventive strategy for recurrent stone formation.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-26273-w. Introduction Urolithiasis is a common urological condition, with an estimated global prevalence of 5–10%1. The recurrence rate within five years is as high as 50%, and the intervals between episodes of stone formation tend to shorten with subsequent recurrences2. This high recurrence rate presents a significant challenge in managing urolithiasis, making it critical to understand the mechanisms underlying stone recurrence. Recent studies have revealed that oxidative stress plays a crucial role in the development of kidney stones3. Oxidative stress occurs when there is an imbalance between the generation of reactive oxygen species and the body’s antioxidant defense systems, leading to cellular and tissue damage. This imbalance has been implicated in several chronic and recurrent diseases4, so it is possible that there a link between oxidative stress and the recurrence of urolithiasis. Furthermore, oxidative stress has been reported to contribute to critical stages of stone formation, including crystal nucleation, growth, aggregation, and retention within renal tissue3. To combat oxidative stress, cells have developed biological defense mechanisms at the molecular level, among which the Keap1–Nrf2 pathway is a key system. Under normal conditions, Nrf2 is bound to Keap1 and degraded. During periods of stress, Keap1 becomes inactivated, allowing Nrf2 to translocate to the nucleus, where it activates a set of antioxidant genes to protect cells from damage. In addition to urolithiasis, oxidative stress has been implicated in several other diseases for which treatments and preventive strategies involving antioxidants (e.g., vitamin C or N-acetylcysteine) or activators of the Keap1–Nrf2 pathway (e.g., curcumin, sulforaphane, bardoxolone methyl, or dimethyl fumarate) have been proposed5–8. Mouse models have been developed to study many diseases, including urolithiasis. It has been reported that an intraperitoneal administration of glyoxylate (GOX) in mice induces the formation of crystals of calcium oxalate (CaOx) in renal tissue within a short period (approximately 5–7 days)9. Our previous studies have demonstrated that the oxidative stress response mediated by the Keap1–Nrf2 pathway is strongly involved in the early stages of crystal nucleation10. Genetic deletion of Nrf2 results in increased crystal formation in the kidneys, whereas pharmacological activation of Nrf2 with bardoxolone methyl (Bard), a known Nrf2 activator, suppresses crystal formation. These findings highlight the potential of modulating the stress response through Nrf2 as a strategy for controlling CaOx crystal formation. Despite these insights, the relationship between oxidative stress and the recurrence of urolithiasis remains underexplored. Furthermore, despite its clinical significance, research on recurrence has been limited, and there is a lack of established models for investigating this issue. In this study, we developed a recurrent renal crystal model by using interval administration of GOX, and we demonstrated a potent crystal-formation-controlling effects of Bard during recurrence. This approach addresses a significant gap in the current understanding of recurrent urolithiasis, particularly by providing insight into how oxidative stress contributes to recurrence and the potential for therapeutic intervention. Our findings suggest that the administration of Bard might serve as an effective strategy for managing recurrent kidney stones, thereby providing valuable information for research and for clinical applications in the treatment of patients with recurrent urolithiasis. Materials and methods Reagents GOX was purchased from Sigma-Aldrich Co. LLC (St. Louis, MO, USA; #G10601) and was dissolved in phosphate-buffered saline for administration to mice. Sodium carboxymethylcellulose was purchased from Sigma-Aldrich Co. LLC (#C5678). Bardoxolone methyl was purchased from ChemScene LLC (Monmouth Junction, NJ, USA; #CS-0598) and was emulsified in 1% aqueous sodium carboxymethylcellulose for administration to mice. Mice Mice (C57BL/6) were purchased from Japan SLC Inc. (Shizuoka, Japan). To induce CaOx crystal formation in the kidney, GOX (100 mg/kg body weight) was injected into mice intraperitoneally daily for five days. To enhance Nrf2 activity in vivo, bardoxolone methyl (10 mg/kg body weight) was orally administered to mice each day for 12 days. Quantitative PCR Total RNA derived from mouse kidney tissues was prepared by using Isogen reagent (#311–02501; Nippon Gene, Tokyo, Japan). The cDNA was synthesized by using ReverTra Ace (#FSQ-301; Toyobo, Osaka, Japan), following the manufacturer’s instructions. Quantitative PCR analysis of each transcript was performed by using THUNDERBIRD (#QPS-101; Toyobo) and QuantStudio 12 K (#QS-TAC02; Applied Biosystems, Waltham, MA, USA) in accord with the manufacturers’ instructions. A GAPDH transcript was used as an internal control in each analysis. The results of the quantitative PCR analyses are reported as the mean ± SEM from experiments performed in triplicate with left kidneys derived from three mice. Probe/primer (Applied Biosystems) sets Mm99999915_g1, Mm00802655_m1, Mm00516005_m1, Mm01253561_m1, Mm00450261_m1, Mm01344233_g1, and Mm00443675_m1 were used for quantification of GAPDH (Glyceraldehyde-3-phosphate dehydrogenase), GCLC (Glutamate-cysteine ligase catalytic subunit), HO-1, Nqo1 (NAD(P)H quinone oxidoreductase 1), Prdx4 (Peroxiredoxin 4), SOD1 (Superoxide dismutase 1), and Txnrd1 (Thioredoxin reductase 1) transcripts, respectively. Detection of CaOx crystals in the kidney Extracted right kidneys from the mice were fixed with 4% neutral-buffered formaldehyde then embedded in paraffin and sliced into 3 μm-thick sections to detect CaOx crystals. Tissues were observed under a polarized-light microscope (BX50; Olympus, Tokyo, Japan). Total areas and crystal areas of each kidney section were measured by using Image J (National Institutes of Health, Bethesda, MD, USA) on unstained specimens. The Pizzolato staining method11 was also used to evaluate CaOx crystal deposition. Study approval The experimental protocols (#2023-34) involving animals were approved by the Kanazawa Medical University Institutional Animal Care and Use Committee. All experiments were performed in accordance with the appropriate institutional guidelines and regulations. The study is reported in accordance with ARRIVE guidelines (https://arriveguidelines.org). Results Appearance and disappearance of GOX-dependent renal CaOx crystals To establish a recurrence model, it was necessary to determine how long CaOx crystals remain in the kidneys of crystal-forming model mice after the induction of crystal formation. We therefore examined the natural course of CaOx crystal persistence. Following the established protocol for the crystal model9, GOX was administered intraperitoneally for five consecutive days, and the amounts of CaOx crystals in the kidneys were measured over a 40-day period. During the first five days of GOX administration, the quantity of renal crystals progressively increased. However, after the final GOX injection, the crystal load had only decreased by about a half (47%) at day 10, and it required at least five weeks to reach less than 97% of its initial level (Fig. 1). This indicates that the disappearance of formed crystals takes a minimum of five weeks. Incidentally, recurrent crystal deposition occurred in the corticomedullary region, as in the initial case. Fig. 1The appearance and disappearance of CaOx crystals in the kidneys of mice injected with GOX daily for five days. (a) The left and right panels show typical examples of polarized-light microscopy images of kidney sections derived from mice before and four days after GOX administration, respectively. The white dots obviously visible in the right panel are CaOx crystals. Scale bar = 1 mm. (b) The area of CaOx crystals in the kidney sections is shown in the histogram for each of the days indicated. Columns and error bars refer to the mean and SEM, respectively. Each open circle marks an individual calculated value (n = 3–5). The appearance and disappearance of CaOx crystals in the kidneys of mice injected with GOX daily for five days. (a) The left and right panels show typical examples of polarized-light microscopy images of kidney sections derived from mice before and four days after GOX administration, respectively. The white dots obviously visible in the right panel are CaOx crystals. Scale bar = 1 mm. (b) The area of CaOx crystals in the kidney sections is shown in the histogram for each of the days indicated. Columns and error bars refer to the mean and SEM, respectively. Each open circle marks an individual calculated value (n = 3–5). Suppression and recovery of transient induction of HO-1 gene expression caused by GOX administration In a previous study, we demonstrated that an initial administration of GOX strongly induces HO-1 mRNA expression in response to Nrf2 activation10. However, on continuous GOX administration, both Nrf2 activation and HO-1 expression induction are significantly diminished. As mentioned earlier, the quantity of CaOx crystals that had formed after five days of GOX administration was reduced by half within 10 days and almost completely disappeared after five weeks. If GOX was readministered continuously at these timings, what differences might be observed in the induction of HO-1 expression? Addressing this question is crucial for establishing the mouse recurrence model. To investigate this, we conducted real-time PCR analyses of mRNA for the Nrf2 target genes (HO-1, GCLC, Nqo1, Prdx4, SOD1, and Txnrd1). The results showed that when GOX was readministered after a 10-day interval, it failed to strongly induce HO-1 expression (Fig. 2a). In contrast, when GOX was readministered after a 5-week interval, HO-1 induction recovered to levels comparable to those of the initial GOX administration (Fig. 2b). Compared with HO-1, the other Nrf2 target genes (GCLC, Nqo1, Prdx4, SOD1, and Txnrd1) did not show any distinct alterations in expression on changing the timing of the GOX administration (Figs. S1–S5). These findings indicate that the induction of HO-1 mRNA expression in response to GOX recovers once the CaOx crystals have cleared. On the basis of the results shown in Figs. 1 and 2, we adopted a model of renal crystal recurrence involving readministration of GOX to mice after a 5-week interval following the initial exposure to GOX. Fig. 2Suppression and recovery of transient induction of HO-1 gene expression caused by GOX administration. The five-day GOX daily administration was carried out twice, with a 10-day interval (a) or a 36-day interval (b). HO-1 gene expression was compared at the indicated points in date and time. HO-1 mRNA levels are represented by a relative value. The columns and error bars refer to the mean and SEM, respectively. Each open circle marks an individual calculated value (n = 3). Suppression and recovery of transient induction of HO-1 gene expression caused by GOX administration. The five-day GOX daily administration was carried out twice, with a 10-day interval (a) or a 36-day interval (b). HO-1 gene expression was compared at the indicated points in date and time. HO-1 mRNA levels are represented by a relative value. The columns and error bars refer to the mean and SEM, respectively. Each open circle marks an individual calculated value (n = 3). Reappearance of renal CaOx crystals in mice reinjected with GOX after a five-week interval How does the pattern of renal CaOx crystal formation in the recurrence model differ from that in the initial episode? Clinical experience has shown that some recurrent patients are more prone to stone formation and recurrence than first-episode patients12,13. This leads to the hypothesis that in the recurrence model, there might be an increase in the total stone volume or a shorter time to stone formation. To test this hypothesis, we measured the crystal volume over time. Contrary to expectations, the crystal volume did not show a consistent daily increase with repeated GOX administration but, instead, fluctuated. There was no acceleration in the rate of stone formation. Moreover, on comparing the total crystal volume, the amount formed during days 40–45 was lower than during days 0–5 (Fig. 3). The crystals in the renal tissue at the time of initial onset and at the time of recurrence were confirmed to consist of calcium oxalate by Pizzolato staining (Fig. S6). However, the crystal morphology could not be determined on examining the 24-hour urine storage samples from the mice. Fig. 3Reappearance of CaOx crystals in the kidneys of mice reinjected with GOX daily for five days after a 36-day interval. The area of CaOx crystals in the kidney sections is shown in the histogram for each of the days indicated. The columns and error bars refer to the mean and SEM, respectively. Each open circle marks an individual calculated value (n = 3–5). Reappearance of CaOx crystals in the kidneys of mice reinjected with GOX daily for five days after a 36-day interval. The area of CaOx crystals in the kidney sections is shown in the histogram for each of the days indicated. The columns and error bars refer to the mean and SEM, respectively. Each open circle marks an individual calculated value (n = 3–5). This reduction during days 40–45 might be attributable to aging rather than the effects of repeated GOX administration. To rule this out this possibility, we compared the crystal-formation patterns during initial GOX administration for 10-week-old mice with those of 16-week-old mice. As with the 10-week-old mice, the 16-week-old mice showed a daily increase in crystal volume, but their total crystal volume was only slightly higher (FigS7). Effects of Bard on recurrent renal CaOx crystal formation Readministration of GOX resulted in a reaccumulation of CaOx crystals, although the extent of crystal formation differed from that induced by the initial administration. Previous studies have reported that the preadministration of antioxidants targeting Nrf2 can suppress the initial formation of CaOx crystals. Similarly, our previous researches showed that atorvastatin, Bard, and curcumin all exhibit such effects10. Among these, Bard showed the most-potent inhibitory effect on CaOx crystal formation. To determine whether Bard also reduces crystal formation during recurrence, we administered Bard one week before readministration of GOX, and we evaluated the amounts of crystals formed in mouse kidneys. The results showed that GOX-dependent CaOx crystal formation was strongly suppressed in the Bard-treated group (Fig. 4). However, when we examined the urinary levels of calcium, oxalic acid, citric acid, and AP(CaOx)14, and the pH and volume of 24-hour urine storage samples, we observed no significant differences in the presence or absence of Bard (Table S1). Fig. 4Effect of Bard on CaOx crystal formation in the kidney of mice reinjected with GOX daily for five days after a 36-day interval. Bard was administered orally for the indicated period. The area of CaOx crystals in the kidney sections is shown in the histogram for each of the days indicated. The columns and error bars refer to the mean and SEM, respectively. Each open circle marks an individual calculated value (n = 3–5). Effect of Bard on CaOx crystal formation in the kidney of mice reinjected with GOX daily for five days after a 36-day interval. Bard was administered orally for the indicated period. The area of CaOx crystals in the kidney sections is shown in the histogram for each of the days indicated. The columns and error bars refer to the mean and SEM, respectively. Each open circle marks an individual calculated value (n = 3–5). Discussion In this study, we first confirmed that the quantity of renal CaOx crystals in mice increased daily during a period of consecutive GOX administration, and we found that it decreased by a half on day 10 of the nonadministration period and nearly disappeared by week 5 (Fig. 1). Next, we observed that HO-1 expression was transiently and strongly induced on the first day of consecutive GOX administration but was barely induced by day 5 (Fig. 2a and b). When daily GOX administration was reintroduced after a 10-day interval, HO-1 expression was barely induced on both the first and fifth days (Fig. 2a). In contrast, after a 5-week interval, HO-1 expression was transiently and strongly induced on the first day of repeated GOX administration but not by day 5 (Fig. 2b). These results indicate that the histopathology and molecular pathology caused by the initial daily administration of GOX can be cured or restored after a 5-week interval: we therefore employed a repeat of the GOX daily administration after a 5-week interval as a model for renal crystal recurrence. In this recurrent model, CaOx crystals forming in the kidney were clearly detectable, but at a slightly lower level than in the primary model (Fig. 3). The difference in the amount of CaOx crystals between the two models was not due to the age of the mice (Fig. S7). Interestingly, Bard intervention in this recurrent model strongly suppressed CaOx crystal formation (Fig. 4). This inhibition greatly exceeded the effect observed in the initial model10. What occurred during the crystal-disappearance process? Spontaneous dissolution of renal CaOx crystals has been reported in rats and humans, as well as in GOX-induced renal crystal mouse models15.There are only a few long-term reports on this phenomenon, making the current findings, which elucidate the duration and extent of crystal disappearance, particularly intriguing. The detailed mechanism of crystal disappearance remains unresolved. The clearance of renal crystals is thought to be mediated by non-specific tubular epithelial function. On the other hand, based on previous studies, it has been suggested that under oxidative stress, damage to tubular epithelial cells by ROS production might occur, inducing increased crystal adhesion and crystal growth, and resulting in decreased clearance16–18. Furthermore, oxidative stress induced by renal crystals strongly influences macrophage differentiation19,20, and drug or genetic modulation of Nrf2 activity is known to reduce renal crystal deposition through M2 polarization21,22. In other words, the induction of Nrf2-HO-1 expression, which is characteristic of the renal crystal formation phase, as recognized in this study, might be a signal to initiate crosstalk to the crystal efflux that might subsequently occur. Although there is some variation in the reports, this is consistent with the timing of M2 macrophages infiltrating the peritubular space within hours after GOX administration and subsequently initiating phagocytosis23. How should we interpret changes in the behavior of oxidative stress response molecules? The reason why the reactivity of the Nrf2-HO-1 pathway slows down when crystals begin to form or remain is assumed to an increased response threshold (i.e., acclimation) caused by the same stress persisting; in molecular terms, this can be partially explained by the increased expression of Keap1 as we previously reported10. Furthermore, since the increase in reaction threshold (habituation) disappears when the crystals disappear, it is thought that the presence of crystals is probably causing chronic oxidative stress. Nrf2 target genes other than HO-1 (GCLC, Nqo1, Prdx4, SOD1, and Txnrd1) showed only slight GOX-dependent transcriptional induction during the crystal-loss phase and recurrence phase. The expression levels of Nrf2 protein and Keap1 mRNA were confirmed by ELISA and RTPCR analyses to show characteristic changes upon GOX administration, suggesting that Keap1-Nrf2 activity and its downstream factors interact with crystal formation, since crystal formation is affected by genetic or pharmacological regulation of Nrf210. It is also expected that the Keap1-Nrf2 activity and its downstream factors are connected to crystal formation, since genetic or pharmacological regulation of Nrf2 affects crystal formation. However, the detailed functional contributions of these oxidative stress-response factors remain unresolved and an analysis based on the molecular activities specific to each factor is considered a future challenge. Why did Bard exhibit stronger effects during recurrence than in the initial episode? Our previous studies have reported that pharmacological activation of Nrf2 can reduce crystal formation during the initial phase. In this study, we found that Bard not only suppressed crystal formation during the initial episode, but also effectively reduced it during recurrence. Bard, a derivative of oleanolic acid and a triterpenoid, robustly activates the Keap1–Nrf2 pathway. Analysis of the Nrf2 target gene did not show a different behavior at recurrence to that at the first onset, and the results do not readily explain this potentiating effect. Speculations are that (1) Bard might be involved in the clearance of renal crystals, or (2) it might have reduced endogenous oxalate production. With respect to speculation (1), the Nrf2 pathway is a representative defense mechanism against oxidative stress that prevents crystal adhesion by reducing oxidative stress and protecting the tubular epithelium; when further crystals have formed, Nrf2 promotes macrophage M2 polarization and phagocytosis of CaOx crystals and suppression of inflammation, as described above. This mechanism might have functioned effectively in the cellular environment with residual initial damage at the time of redosing. With regard to speculation (2), although LDH acts as a dismutase that converts GOX into oxalate, endogenous oxalate formation by the LDH pathway can be controlled by thiol-group-containing inhibitors (GSH, cysteine, or cysteamine), suggesting the possibility a reduced risk of oxalate stone formation by this mechanism24. This means that Bard might promote the transcription of glutathione-related genes and, indirectly, lower LDH activity. The fact that Bard treatment has been shown to elevate GSH in cellular experiments is also consistent with this hypothesis10. There have been reports of increased levels of GSH and of enzymes involved in GSH metabolism in a Bard-treated group in models of renal injury (the ischemia-reflux model and the salt-induced renal injury model)25,26 which might be one reason why Bard was more effective at recurrence following a history of renal injury. In any case, the significant crystal suppression observed in the present study with Bard suggests that the oxidative stress response mediated by the Keap1-Nrf2 pathway might also play an important role in the crystal formation process at relapse, although this remains a matter of speculation. The experimental system used in the present study has several limitations. Although experiments with cultured cells are generally useful for further explorations of results obtained in animal studies, the differences in responsiveness to stimuli of the two systems makes the interpretation of experimental results difficult. In the case of GOX administration to HK-2 and M-1 cells derived from the renal proximal tubular epithelium, the changes in the oxidative stress response over time were different from those in the mouse model, and it was not easy to establish a recurrence model of the disease in cultured cells, so the experiments using cultured cells had to be abandoned. Histological analysis using antibodies is also useful for understanding the pathophysiology of various diseases at the molecular and cellular levels. However, because COM crystals display autofluorescence, it is difficult to distinguish the resultant signal from the desired signal, so fluorescent immunohistochemistry could not be adopted as an analytical method. In addition, analysis of urinary constituents is also useful for understanding renal function. The data obtained by this method are shown in Table S1; however, only small volumes of urine could be collected from mice, limiting the number of endpoints. In addition, the sample quality was not considered worthy of evaluation due to contamination by feces and spilled food, even though a dedicated urine-collection device was used. Due to these limitations, the relationship between COM crystal formation and the oxidative stress response remains speculative, as mentioned above. Urolithiasis has a high recurrence rate, there is a heightened need for therapeutic interventions targeting the risks associated with recurrence. In clinical trials, Bard, the compound used in this study, has shown promise in improving renal function, making it a feasible option for clinical application. Interest is growing in experiments to observe the effects of Bard in animal species other than mice, including humans. The phenomenon of renal crystal dissolution has also been reported in humans18, and effects similar to those observed in this mouse recurrence model may be expected. However, these findings are based on experiments using a mouse renal crystal model, and limitations due to interspecies differences exist. Mice are known to have difficulties in forming renal crystals. Presumably, mice have a protective capacity against renal crystal formation caused by hyperoxaluria. In this respect, species differences impose limitations on the use of the mouse as a recurrence model. We believe that future studies of HO-1 behavior in mouse models other than those in which oxalate precursors are administered could help answer the question of whether our findings show the existence of GOX-specific cytotoxicity or of a nonspecific response during the crystal formation phase, and would help to eliminate the limitations arising from the differences between species. We would like to address this issue in the future. Recurrent stones induce oxidative stress, which, in turn, exacerbates renal damage and promotes further stone formation, creating a self-perpetuating cycle. This underscores the importance of addressing oxidative stress in the management of recurrent nephrolithiasis. Breaking this vicious circle through preventive strategies, particularly by elucidating molecular-level mechanisms and targeting Nrf2 as a drug-discovery focus, holds significant potential for improving outcomes in this population of patients. Supplementary Information Below is the link to the electronic supplementary material.Supplementary material 1 (JPG 790.4 kb)Supplementary material 2 (JPG 791.9 kb)Supplementary material 3 (JPG 828.8 kb)Supplementary material 4 (JPG 822.9 kb)Supplementary material 5 (JPG 811.0 kb)Supplementary material 6 (JPG 801.5 kb)Supplementary material 7 (JPG 794.9 kb)Supplementary material 8 (JPG 789.5 kb)Supplementary material 9 (JPG 788.8 kb)Supplementary material 10 (JPG 793.9 kb)Supplementary material 11 (JPG 3744.8 kb)Supplementary material 12 (JPG 899.7 kb)Supplementary material 13 (DOC 35.5 kb)Supplementary material 14 (DOCX 26.5 kb) Supplementary material 1 (JPG 790.4 kb) Supplementary material 2 (JPG 791.9 kb) Supplementary material 3 (JPG 828.8 kb) Supplementary material 4 (JPG 822.9 kb) Supplementary material 5 (JPG 811.0 kb) Supplementary material 6 (JPG 801.5 kb) Supplementary material 7 (JPG 794.9 kb) Supplementary material 8 (JPG 789.5 kb) Supplementary material 9 (JPG 788.8 kb) Supplementary material 10 (JPG 793.9 kb) Supplementary material 11 (JPG 3744.8 kb) Supplementary material 12 (JPG 899.7 kb) Supplementary material 13 (DOC 35.5 kb) Supplementary material 14 (DOCX 26.5 kb)